Nova One Advisor
U.S. Blood Collection Market Size to Worth Around USD 6.00Bn by 2034

U.S. Blood Collection Market Size, Share & Trends Analysis Report By Site (Venous, Capillary), By Application (Diagnostics, Treatment), By End Use, By Age, By Demography, By States, And Segment) - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2034

Status: Published Category: Healthcare Insight Code: 8787 Format: PDF / PPT / Excel

U.S. Blood Collection Market Size and Growth Forecast 2025-2034

The U.S. blood collection market size was USD 2.75 billion in 2024, calculated at USD 2.97 billion in 2025 and is expected to reach around USD 6.00 billion by 2034, expanding at a CAGR of 8.11% from 2025 to 2034, The growth of the U.S. blood collection market is driven by the rising incidences of chronic and infectious diseases, advancements in blood collection devices such as fingerstick technologies and vacuum blood collection tubes, and focus on preventive healthcare. The increasing adoption of autonomous blood drawing technology is expanding the market potential.

U.S. Blood Collection Market Size 2024 To 2034

U.S. Blood Collection Market Key Takeaways

  • The venous segment dominated the market with a revenue share of 83% in 2024 and is expected to grow at the fastest CAGR over the forecast period.
  • The capillary segment is anticipated to grow at a lucrative rate over the forecast period.
  • The diagnostics segment dominated the market in 2024 and is expected to grow at the fastest CAGR over the forecast period
  • The treatment segment is anticipated to grow at a lucrative CAGR over the forecast period.
  • The hospitals segment dominated the market with a share of 29% in 2024.
  • The blood bank centers segment is anticipated to grow at a significant rate over the forecast period.
  • The 19 to 65 segments held the largest market share in 2024 and are expected to grow at the fastest CAGR over the forecast period.
  • The 0-18 segment is anticipated to grow at a significant CAGR over the forecast period.

Market Overview

The U.S. blood collection market is a vital pillar of the national healthcare infrastructure, serving as a backbone for both diagnostic and therapeutic applications across hospitals, laboratories, blood banks, and mobile health units. Blood collection, encompassing the procurement of whole blood and its components, plays an indispensable role in disease diagnosis, transfusions, organ transplantation, trauma management, cancer treatment, and chronic condition monitoring. As the U.S. healthcare system transitions toward preventive medicine and value-based care, the accuracy and efficiency of blood collection technologies have gained new significance.

In 2024, the U.S. blood collection ecosystem has expanded beyond traditional hospital settings to include mobile services, point-of-care clinics, and community blood drives. Increasing chronic disease burden, aging demographics, and growing healthcare access in rural regions have spurred demand for advanced, reliable, and minimally invasive blood collection techniques. The rise of home-based diagnostics and wearable health solutions has further diversified the methods and frequency of blood sampling.

Market stakeholders—from device manufacturers to government health agencies—have also been influenced by the recent COVID-19 pandemic, which exposed vulnerabilities in the national blood supply chain. In response, innovations in cold-chain logistics, plasma separation technologies, and closed-loop automated blood collection systems are being rapidly adopted. Furthermore, public awareness campaigns and donor retention initiatives are being revitalized, especially in underserved states, to ensure a resilient national blood system.

  • Adoption of Safety-Engineered Devices: Increasing demand for needle-stick injury prevention and closed-system collection kits is transforming product design.

  • Rise of Mobile Blood Collection Units: Community outreach and telehealth integrations have boosted mobile collection services, especially in rural and underserved areas.

  • Automation in Blood Processing: Integration of automated blood separation, labeling, and testing systems within collection centers to enhance throughput and safety.

  • Micro-Sampling Technologies: Growing use of lancets, micro-containers, and capillary devices for pediatric and at-home diagnostics.

  • Increased Demand for Plasma-Derived Therapies: Expansion in plasma collection tubes and bags due to rising immunoglobulin-based treatments.

  • Integration of Digital Tracking & Inventory Systems: Use of RFID, barcoding, and real-time tracking software in managing blood units across hospitals and banks.

  • Customization for Pediatric and Geriatric Needs: Development of age-appropriate needles, containers, and warming devices for better compliance and comfort.

  • Public-Private Collaborations: Government-supported partnerships with healthcare providers and NGOs to stabilize national blood supplies.

How is AI Transforming the U.S. Blood Collection Market?

Artificial intelligence (AI) integration in the U.S. blood collection market is driven by factors such as advanced healthcare infrastructure, increased adoption of digital technologies in healthcare systems, and rising collaboration of diagnostic companies with technology providers. AI algorithms can be applied for analyzing blood samples for detecting different conditions such as infectious diseases and autoimmune disorders, as well as some types of cancer. Companies in the U.S. are developing AI-powered robotic systems for automating blood collection, further helping to address the lack of phlebotomists and for enhancing the efficiency of hospital and lab workflows. AI-powered image analysis of blood samples such as through microscopes can assist in identification of cells and detection of abnormalities, which can improve the diagnosis of several conditions.

U.S. Blood Collection Market Report Scope

Report Attribute Details
Market Size in 2025 USD 2.97 Billion
Market Size by 2034 USD 6.00 Billion
Growth Rate From 2025 to 2034 CAGR of 8.11%
Base Year 2024
Forecast Period 2025 to 2034
Segments Covered Site, Application, End use, Age, Demography, States
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled Sekisui Medical Co., Ltd., Becton, Dickinson and Company (BD), Greiner Bio-One, QIAGEN, Nipro Corporation, Terumo Corporation, Haemonetics Corp., Zhejiang Gongdong Medical Technology Co., Ltd., Drucker Diagnostics, AdvaCare Pharma

Market Driver: Rising Chronic Disease Prevalence and Surgical Procedures

A primary driver of growth in the U.S. blood collection market is the increasing prevalence of chronic conditions—such as cancer, anemia, hemophilia, and renal disease—that necessitate regular blood transfusions and diagnostics. According to CDC data, over 60% of Americans suffer from at least one chronic illness, creating sustained demand for both venous and capillary blood collection. Additionally, the U.S. sees a high volume of elective and emergency surgeries annually, most of which require preoperative and postoperative blood testing or transfusion support. This has led to an increased need for efficient, safe, and standardized blood collection protocols in both inpatient and outpatient settings.

Market Restraint: Blood Donor Shortage and Supply Chain Gaps

Despite medical advancements, one of the most persistent challenges remains the shortage of eligible blood donors, particularly during public health emergencies or natural disasters. Seasonal fluctuations in donor turnout, pandemic fears, and geographic disparities in blood availability often result in critical shortages. The American Red Cross has highlighted that blood inventory frequently falls below the minimum threshold, particularly for rare blood types. Furthermore, complex storage, handling, and transportation requirements—especially for plasma and platelets—make it difficult to maintain a consistent supply across all states, particularly in remote or underserved regions.

Market Opportunity: Growth of Home-Based and Decentralized Diagnostics

As healthcare delivery models shift toward decentralization, there’s a growing opportunity for capillary blood collection tools that enable testing at home, in retail clinics, or remote locations. The expansion of telehealth and self-testing kits has created a fertile market for lancets, micro-collection tubes, and warming devices that simplify blood collection for non-clinical users. Emerging technologies such as volumetric absorptive microsampling (VAMS) are gaining traction, offering accurate sampling with minimal invasiveness. This trend is particularly relevant for chronic disease monitoring, prenatal screening, and infectious disease surveillance, opening up a new segment of end-users who demand convenience without compromising on sample integrity.

U.S. Blood Collection Market By Site Insights

Venous blood collection dominated the U.S. market, accounting for the majority of diagnostic and transfusion-related procedures. The segment encompasses a wide range of devices such as double-ended needles, blood collection tubes (serum-separating, EDTA, heparin), and blood bags. Venipuncture remains the gold standard in hospital and laboratory settings due to its ability to yield high-volume samples suitable for multi-panel tests and component separation. Moreover, advances in vacuum-assisted collection tubes and safety-engineered needles have enhanced collection efficiency and minimized contamination and exposure risks.

Capillary blood collection is the fastest-growing site segment, driven by the rise of decentralized diagnostics and pediatric applications. Tools like lancets, micro-hematocrit tubes, and warming devices are gaining favor in point-of-care testing, home diagnostics, and mobile clinics. These tools are ideal for quick glucose testing, hemoglobin evaluation, and disease marker screening in infants and the elderly. The growing demand for less invasive methods and faster turnaround in outpatient settings has led companies like SARSTEDT and Greiner Bio-One to launch user-friendly capillary blood collection kits with integrated stabilization features.

U.S. Blood Collection Market By Application Insights

Diagnostics lead the application segment, owing to the high frequency of routine blood tests, disease screenings, and pre-surgical assessments performed across the healthcare ecosystem. Every year, millions of diagnostic tests in the U.S. depend on venous and capillary blood samples to monitor cholesterol, glucose, hormones, infections, and organ function. This has spurred consistent demand for high-accuracy tubes, sample preservation systems, and vacuum-assisted syringes. The increased emphasis on early disease detection and regular health monitoring has amplified the significance of diagnostic blood collection.

Treatment-related applications are growing rapidly, especially with the increasing use of blood and plasma therapies for chronic disease management and emergency care. Transfusions for trauma victims, cancer patients, and surgical recipients rely on timely and safe collection of compatible blood units. Blood bags and component separation kits are in higher demand, particularly in oncology, nephrology, and cardiovascular wards. This segment also benefits from innovations in pathogen inactivation and automated blood bag systems, ensuring higher safety and process control.

U.S. Blood Collection Market By End Use Insights

Hospitals are the dominant end-use segment, being the primary site for inpatient diagnostics, surgical procedures, and transfusions. They require a vast inventory of blood collection tools—from hypodermic needles to blood bags—along with integrated information systems for tracking samples. With increasing patient admissions and critical care procedures, hospitals continue to procure large quantities of blood collection consumables and automated systems to streamline diagnostics and treatment.

Mobile services and emergency departments are emerging as the fastest-growing users, thanks to the expansion of community outreach and disaster response capabilities. Mobile blood collection vehicles equipped with portable centrifuges, donor beds, and digital monitoring systems are serving rural populations and urban centers alike. Similarly, emergency departments depend on fast, reliable blood collection for trauma care and accident victims. Companies like Terumo and Haemonetics are innovating mobile-ready blood collection systems with closed-loop safety and digital traceability.

U.S. Blood Collection Market By Age Insights

The 19 to 65 age group leads the market, representing the largest donor pool and highest recipient group for diagnostic tests and surgeries. Adults in this demographic undergo frequent screenings, chronic disease monitoring, and organ function testing, necessitating regular blood sampling. Blood collection products in this age group emphasize efficiency, speed, and compatibility with high-throughput analyzers.

The 66 years and above group is witnessing faster growth, reflecting aging population trends and higher disease burden. Geriatric patients often require transfusions for anemia, surgical support, and palliative care, increasing the need for safe and minimally invasive collection tools. Specially designed needles and warming devices are being developed to address fragile veins and coagulation issues in the elderly.

U.S. Blood Collection Market By Demography Insights

Urban populations dominate the market, due to higher healthcare access, frequent hospital visits, and concentration of diagnostic labs. Urban healthcare facilities adopt the latest blood collection technologies and maintain larger inventories, supporting fast-paced diagnostic and treatment needs.

Rural segments are growing faster, propelled by mobile collection units, state health programs, and rising penetration of community clinics. Partnerships between NGOs and state governments have enabled door-to-door collection initiatives and rural blood drives using portable devices and real-time data tracking systems.

Country-Level Analysis

The U.S. blood collection market is shaped by its highly decentralized yet advanced healthcare system. Federal agencies like the FDA and CDC regulate blood safety, while nonprofit organizations like the American Red Cross and AABB play critical roles in operationalizing donation drives and managing blood supplies. Technological innovation is centered in major hubs like California, Massachusetts, and New Jersey, where companies test and launch new products.

Nationwide trends reflect increased investments in public health infrastructure, modernization of blood bank technologies, and enhanced donor management systems. Geographic disparities in access and supply chain capacity are being addressed through state-level programs and federal funding, especially in the Southeast and Midwest. The U.S. market is also a testbed for next-gen blood collection products, including microfluidic sampling, AI-enabled tracking, and drone-based transportation in emergency scenarios.

U.S. Blood Collection Market Top Key Companies:

  • Sekisui Medical Co., Ltd.
  • Becton, Dickinson and Company (BD)
  • Greiner Bio-One
  • QIAGEN
  • Nipro Corporation
  • Terumo Corporation
  • Haemonetics Corp.
  • Zhejiang Gongdong Medical Technology Co., Ltd
  • Drucker Diagnostics
  • AdvaCare Pharma

U.S. Blood Collection Market Recent Developments

  • In August 2025, Freenome entered into an exclusive licensing agreement with Exact Sciences for advancing the commercialization of its colorectal (CRC) blood-based screening test which includes the U.S. commercial rights and the foundational technology.
  • In May 2025, Cellecta, Inc. launched the DriverMap™ EXP Human Genome-Wide 19K Dried Blood Microsample Profiling kit, a targeted RNA expression profiling assay which simplifies the discovery of clinically relevant transcriptome biomarkers by offering a molecular snapshot of all 19,000 human protein-coding genes from as little as 30 microliters of dried whole blood.
  • In February 2025, Tasso Inc., a leader in patient-centric, clinical grade blood collection solutions, and ARUP Laboratories formed a partnership for developing and operationalizing high-quality, at-home, blood testing services for accelerating decentralized clinical research biomarker testing.
  • In December 2024, BD (Becton, Dickinson and Company) in partnership with Babson Diagnostics declared an expansion of their fingertip blood collection and testing technologies portfolio for use by health systems in U.S. and other large provider networks in settings such as doctor offices, urgent cares and other ambulatory care settings. The innovative blood testing will enable test results from as few as six drops of capillary blood collected from a patient’s finger by leveraging BD’s MiniDraw Capillary Blood Collection System with Babson’s BetterWay technologies.

U.S. Blood Collection Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the U.S. Blood Collection market.

By Site 

  • Venous
    • Needles and Syringes
      • Double-Ended Needles
      • Winged Blood Collection Sets
      • Standard Hypodermic Needles
      • Other Blood Collection Needles
    • Blood Collection Tubes
      • Serum-separating
      • EDTA
      • Heparin
      • Plasma-separating
    • Blood Bags
    • Others
  • Capillary
    • Lancets
    • Micro-Container Tubes
    • Micro-Hematocrit Tubes
    • Warming Devices
    • Others

By Application 

  • Diagnostics
  • Treatment

By End Use 

  • Hospitals
  • Clinical Laboratories
  • Blood Banks Centers
  • Clinics
  • Mobile Service
  • Emergency Departments
  • Others

By Age 

  • 0-18
  • 19 to 65
  • 66 years and above

By Demography 

  • Urban
  • Rural

By States 

  • California
  • Texas
  • Florida
  • New York
  • Pennsylvania
  • Illinois
  • Ohio
  • Georgia
  • North Carolina
  • South Carolina
  • Michigan
  • Alabama
  • Arkansas
  • Kentucky
  • Louisiana
  • Mississippi
  • Tennessee
  • West Virginia
  • Virginia
  • Colorado
  • Alaska
  • Vermont
  • South Dakota
  • Maine
  • Oregon
  • Rest of U.S.
  • Insight Code: 8787
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

FAQ's

The U.S. blood collection market is projected to grow from USD 2.97 billion in 2025 to around USD 6.00 billion by 2034, reflecting a CAGR of 8.11%. This steady growth is fueled by chronic disease prevalence, technological advancements in blood collection devices, and the expansion of decentralized and preventive healthcare models.

Key drivers include: Rising chronic and infectious disease burden requiring frequent diagnostics and transfusions. Increasing surgical volumes across elective and emergency care. Technological advancements such as vacuum blood collection tubes, fingerstick devices, and AI-enabled systems. Shift toward preventive and home-based healthcare models. These factors are collectively strengthening demand for both venous and capillary blood collection.

AI-powered robotic phlebotomy to address workforce shortages and improve efficiency. Safety-engineered needles and closed-loop systems to reduce contamination and injuries. Micro-sampling and capillary devices enabling at-home and pediatric diagnostics. Digital tracking (RFID/barcoding) to enhance traceability and inventory management. Plasma collection advancements supporting growth in immunoglobulin therapies.

AI is enabling: Automated robotic blood drawing systems to reduce dependency on skilled phlebotomists. AI-driven image analysis of samples to detect abnormalities in real-time. Predictive analytics for inventory management and donor engagement. Integration with telehealth platforms, allowing seamless decentralized diagnostics. This makes AI a pivotal enabler for efficiency, scalability, and accuracy in blood collection.

Blood donor shortages, worsened by demographic trends and emergency-driven fluctuations. Supply chain vulnerabilities, especially in plasma and platelet storage/transport. Geographic disparities, with rural and underserved states facing access limitations. Regulatory compliance costs, particularly for safety and sterility protocols. These challenges create both risks and opportunities for innovators who can address them.

The fastest-growing opportunity lies in home diagnostics and decentralized testing, driven by telehealth adoption. Capillary blood collection devices, microsampling kits, and wearable diagnostics are becoming mainstream. Investors can expect strong growth in companies innovating consumer-friendly, accurate, and regulatory-compliant solutions.

By site: Capillary collection (due to home testing and pediatrics). By application: Diagnostics (largest share) and treatment (fastest growth in transfusions). By end-use: Mobile services and emergency departments (community and disaster response growth). By age group: 19–65 remains dominant, while geriatric (66+) segment grows rapidly with aging population. By geography: Rural adoption via mobile units and state-led programs shows rising demand.

Major players include Becton, Dickinson and Company (BD), Terumo, Haemonetics, Greiner Bio-One, and QIAGEN. Strategies focus on: Expanding AI-powered and at-home blood collection technologies. Partnerships (e.g., Tasso & ARUP Labs, BD & Babson Diagnostics) to integrate collection with digital health. Expanding plasma collection and pathogen inactivation technologies. This competitive landscape is seeing consolidation and tech-driven differentiation.